Akero Therapeutics, Inc.
(NASDAQ : AKRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.10%144.410.7%$909.96m
PFEPfizer Inc. -0.85%37.170.9%$777.93m
BMYBristol-Myers Squibb Co. -0.54%60.311.0%$640.84m
MRKMerck & Co., Inc. 0.31%78.510.7%$631.63m
ABBVAbbVie, Inc. -1.77%82.761.9%$580.58m
LLYEli Lilly & Co. -1.10%142.011.1%$495.27m
AZNAstraZeneca Plc -0.18%52.101.2%$200.77m
NVSNovartis AG -1.17%84.690.2%$143.93m
GSKGlaxoSmithKline Plc -0.89%35.720.2%$134.95m
NVONovo Nordisk A/S -0.39%70.970.1%$70.67m
RGENRepligen Corp. 0.42%173.227.1%$63.68m
RPRXRoyalty Pharma Plc -2.72%39.000.2%$57.60m
PRAXPraxis Precision Medicines, Inc. 3.57%28.740.0%$49.09m
SNYSanofi -0.44%49.660.2%$48.55m
AMAGAMAG Pharmaceuticals, Inc. 0.11%13.6622.1%$44.90m

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.